{{Short description|American medical society}} The '''National Lipid Association''' (NLA) is an American non-profit multidisciplinary medical society that aims to enhance the practice of lipid management in [[clinical medicine]]. The NLA focuses on the prevention of [[cardiovascular disease]] and other lipid-related disorders.<ref name="Statement">[https://news.cuanschutz.edu/pharmacy/saseen-co-authors-national-lipid-association-official-scientific-statement-on-statin-intolerance "Saseen Co-Authors National Lipid Association Official Scientific Statement on Statin Intolerance"]. news.cuanschutz.edu. Retrieved 9 January 2023.</ref>
==Overview==
The National Lipid Association was formed in 1997 and has over 2,000 members.<ref name="Who">[https://www.lipid.org/about "Who We Are"]. lipid.org. Retrieved 9 January 2023.</ref><ref>[https://www.athero.org/about-ias/member-societies/usa-national-lipid-association-nla/ "USA – National Lipid Association (NLA)"]. athero.org. Retrieved 9 January 2023.</ref> It provides medical education for healthcare professionals and physicians to advance knowledge and certification in clinical [[lipidology]].<ref name="Who"/> Joseph Saseen is the current president of NLA.<ref>[https://www.lipid.org/nla/nla-welcomes-new-leadership "The NLA Welcomes New Leadership"]. lipid.org. Retrieved 9 January 2023.</ref><ref>[https://news.cuanschutz.edu/pharmacy/in-the-news/professor-joe-saseen-named-president-of-national-lipid-association "Professor Joseph Saseen named president of National Lipid Association"]. news.cuanschutz.edu. Retrieved 9 January 2023.</ref> In 2014, the NLA proposed a working definition of [[statin]] intolerance and made general recommendations for health professionals.<ref>{{cite journal|author=Guyton JR, Bays HE, Grundy SM, Jacobson TA|year=2014|title=The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update|journal=J Clin Lipidol|volume=8|issue=3|pages=72–81|doi=10.1016/j.jacl.2014.03.002|pmid=24793444|doi-access=free}}</ref><ref>[https://www.businesswire.com/news/home/20140502005025/en/The-National-Lipid-Association-Addresses-the-Safety-of-Statins-and-Provides-Recommendations-to-Clinicians-and-Patients "The National Lipid Association Addresses the Safety of Statins and Provides Recommendations to Clinicians and Patients"]. businesswire.com. Retrieved 9 January 2023.</ref>
The NLA have stated that by 2012, a wealth of evidence including numerous clinical trials examined by the Cholesterol Treatment Trialists' Collaboration has confirmed the [[lipid hypothesis]].<ref>[https://www.lipid.org/lipid-spin/summer-2022/lipid-hypothesis "The Lipid Hypothesis"]. lipid.org. Retrieved 22 January 2024.</ref>
The NLA publishes the ''[[Journal of Clinical Lipidology]]''.<ref>[https://www.sciencedirect.com/journal/journal-of-clinical-lipidology "Journal of Clinical Lipidology"]. sciencedirect.com. Retrieved 9 January 2023.</ref>
==Scientific statements==
In 2019, the NLA's Nutrition and Lifestyle Task Force published a scientific statement based on a comprehensive review of recent clinical evidence on the effects of low and very-[[low-carbohydrate diet]]s on the management of body weight and other cardiometabolic risk factors.<ref name="Kirkpatrick 2019">{{cite journal | vauthors = Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE, Willard KE, Maki KC | display-authors = 3 | title = Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force | journal = Journal of Clinical Lipidology | url= https://www.lipidjournal.com/article/S1933-2874(19)30267-3/fulltext| volume = 13 | issue = 5 | pages = 689–711.e1 | date = 2019 | doi = 10.1016/j.jacl.2019.08.003 | pmid = 31611148| s2cid = 203514787 | doi-access = free }}</ref><ref name="Quackwatch">[https://quackwatch.org/ncahf/digest20/20-01/ "Low-carbohydrate diet claims scrutinized"]. quackwatch.org. Retrieved 9 January 2023.</ref> The statement concluded that low and very-low-carbohydrate die are not superior to other dietary approaches for weight loss and are difficult to maintain in the long term.<ref name="Kirkpatrick 2019"/><ref name="Quackwatch"/>
In 2021, the NLA published a scientific statement on lipid measurements in the management of cardiovascular diseases.<ref>[https://www.acc.org/latest-in-cardiology/articles/2021/11/22/13/11/utilization-of-clinical-testing-in-the-setting-of-dyslipidemia "Utilization of Clinical Testing in the Setting of Dyslipidemia"]. acc.org. Retrieved 9 January 2023.</ref>
In 2022, the NLA published a scientific statement on statin intolerance, updating the definition which now classifies statin intolerance as either partial or complete.<ref>[https://www.acc.org/latest-in-cardiology/articles/2022/08/08/12/27/nla-2022-definition-of-statin-intolerance "NLA 2022 Definition of Statin Intolerance"]. acc.org. Retrieved 9 January 2023.</ref> The 2022 statement recommends different strategies to help patients stay on statin medications, and alternative medications to those who cannot tolerate statins.<ref name="Statement"/><ref>[https://archive.today/20220623115934/https://www.medscape.com/viewarticle/975674 "New National Lipid Association Statement on Statin Intolerance"]. medscape.com. Retrieved 9 January 2023.</ref>
==Selected publications== *{{cite journal|author=Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC|year=2022|title=NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient|journal= J Clin Lipidol|url=https://www.lipidjournal.com/article/S1933-2874(22)00167-2/fulltext|volume=16|issue=4|pages=361–375|doi=10.1016/j.jacl.2022.05.068|pmid=35718660|s2cid=249868408 |doi-access=free}}
==References== {{Reflist}}
==External links== *[https://www.lipid.org/ National Lipid Association]
[[Category:Heart disease organizations]] [[Category:Lipid hypothesis]] [[Category:Medical associations based in the United States]] [[Category:Professional associations based in the United States]]